Clinical trial
Abraxane and Alimta in Advanced Solid Tumors
NCT00470548 · University of California, Davis, Other · Terminated
Key facts
| NCT number | NCT00470548 |
|---|---|
| Title | Abraxane and Alimta in Advanced Solid Tumors |
| Official title | Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer |
| Lead sponsor | University of California, Davis, Other |
| Collaborators | Celgene Industry Eli Lilly and Company |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | Abraxane, Alimta |
| Enrollment | 49 |
| Start date | Apr 1, 2007 |
| Primary completion | Oct 1, 2014 |
| Completion | Oct 1, 2014 |
| First posted | May 7, 2007 |
| Last update posted | Jan 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: